Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.
A year after the most radical transformation of U.S. antitrust filing rules in nearly half a century, the domestic merger and acquisition (M&A) market is finally finding its rhythm. The Federal Trade Commission (FTC) and the Department of Justice (DOJ) implemented a sweeping overhaul of the Hart-Scott-Rodino (HSR)
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its transition into a pure-play healthcare giant, the company has emerged with a leaner, more aggressive growth profile. Analysts
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of early 2026, the San Diego-based biotech has transitioned from a promising "dark horse" into a formidable contender challenging the global duopoly of Eli Lilly (NYSE: [...]
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally underscores the company's status as the undisputed titan of the large-cap healthcare sector, a position bolstered by
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based biotechnology giant is now aggressively shedding its image as a "one-hit wonder" vaccine maker. Following a volatile 2024 and 2025, the company has captured Wall [...]
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M adjuvant technology.
NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026, soundly beating Wall Street’s expectations. The healthcare giant accompanied its earnings beat with a bold 2026 financial forecast, projecting
In a move that signals the arrival of the "Bio-Computing" era, NVIDIA (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have officially launched a landmark $1 billion AI co-innovation lab. Announced during the J.P. Morgan Healthcare Conference in January 2026, the five-year partnership represents a massive bet on the convergence of generative AI and life sciences. [...]
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with Zoetis (NYSE:ZTS).
The American manufacturing sector has finally crossed the threshold into expansion territory, with the latest Institute for Supply Management (ISM) Manufacturing PMI rising to 50.9. This mark represents the strongest performance for the sector in nearly a year, sparking a flurry of optimism on Wall Street and suggesting that
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results. This report serves as a critical barometer for the healthcare giant’s first full year as a
